| 晚期非小细胞肺癌病人一线治疗的优化策略 |
| |
| 引用本文： | 韩一平. 晚期非小细胞肺癌病人一线治疗的优化策略[J]. 药学服务与研究, 2011, 11(4): 241-245. DOI: 10.5428/pcar20110401 |
| |
| 作者姓名： | 韩一平 |
| |
| 作者单位： | 第二军医大学长海医院呼吸内科,上海,200433 |
| |
| 摘 要： | 肺癌是全球头号癌症杀手,合理优化晚期非小细胞肺癌病人的药物治疗策略,有望改善病人的生存预后。至今,含铂两药化疗仍是非小细胞肺癌群体有效率最高的治疗首选;对于选择性人群,如表皮生长因子受体突变者,靶向药物表皮生长因子受体酪氨酸激酶抑制剂更具优势。两者应用新模式和策略仍在进一步研究和完善中。
|
| 关 键 词： | 肺肿瘤 抗肿瘤联合化疗方案 靶向药物 临床试验 综述 |
Optimization strategies of first-line treatment of patients with advanced non-small cell lung cancer |
| |
| HAN YiPing. Optimization strategies of first-line treatment of patients with advanced non-small cell lung cancer[J]. Pharmaceutical Care and Research, 2011, 11(4): 241-245. DOI: 10.5428/pcar20110401 |
| |
| Authors: | HAN YiPing |
| |
| Affiliation: | HAN YiPing(Department of Respiratory Diseases,Changhai Hospital,Second Military Medical University,Shanghai 200433,China) |
| |
| Abstract: | Lung cancer is a leading cause of cancer-related death worldwide.It is possible to achieve marginal improvement in overall survival of patients with advanced non-small-cell lung cancer(NSCLC) by optimizing strategies of drugs treatment.The platinum-based doublet chemotherapy has been considered as the standard first-line treatment for NSCLC with the highest treatment efficacy.Erlotinib and gefitinib appear to be especially effective for tumors with gene mutations of activated epidermal growth factor recepto... |
| |
| Keywords: | lung neoplasms antineoplastic combined chemotherapy protocols target drug clinical trial review |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
